The effect of surgical interventions for gynaecological malignancies on red blood cell indices and hemostaseologic parameters

The goal of this study was to monitor changes of common hemostaseologic parameters, serum protein concentration red blood cell (RBC) indices and erythrocyte sedimentation rate (ESR) in women with malignant and non-malignant gynecologic disease preoperatively and in the early postoperative period (five days).One hundred fifty-two women with a primary diagnosis of gynaecological malignancy and a matched group of women undergoing surgery for non-malignant disorders were enrolled in the study. Patients with severe comorbity or venous thrombosis events in the recent history (< six months) were excluded. Preoperatively, coagulation markers including fibrinogen- and D-Dimer-levels were statistically significantly higher, while pTTT was prolonged in all cancer patients compared to the benign tumor patients. Mean albumin/globulin ratio (A/G-R) was lower in each of the cancer types being lowest in ovarian cancer patients while RBC indices (MCH, MCV, and MCHC) were comparable with those of the benign disease group. However, ESR was significantly higher in all types of cancer compared to the controls. Postoperatively, in the cancer groups, mean values of coagulation markers increased and remained significantly higher as compared to the preoperative values until day 5. A/G-R slightly but statistically significantly dropped postoperatively, being lowest in patients with ovarian cancer. While in the cancer patients, ESR statistically significantly increased postoperatively and remained high until day 5 it remained unchanged after surgery for benign disease. The preoperative use of common routine laboratory markers may allow differentiation of dignity in patients with benign and malign gynecologic disease. Moreover, the divergence of the results postoperatively correlate with the extent of the intervention and the tumor load being most remarkable after ovarian cancer surgery.

Gynaecological malignancies; Surgery; Coagulation; RBC indices; ESR.

[1] Wang X., Fu S., Freedman R.S., Kavanagh J.J.: “Venous thromboembolism syndrome in gynecological cancer”. Int. J. Gynecol. Cancer, 2006, 16, 458.

[2] Connors J.M.: “Prophylaxis against venous thromboembolism in ambulatory patients with cancer”. N. Engl. J. Med., 2014, 370, 2515.

[3] Khorana A.A., Francis C.W., Culakova E., Fisher R.I., Kuderer N.M., Lyman G.H.: “Thromboembolism in hospitalized neutropenic cancer patients”. J. Clin. Oncol., 2006, 24, 484.

[4] Esmon C.T.: “Basic mechanisms and pathogenesis of venous thrombosis”. Blood Rev., 2009, 23, 225.

[5] Ha J.E., Lee Y.S., Lee H.N., Park E.K.: “Diagnostic laparoscopy of patient with deep vein thrombosis before diagnosis of ovarian cancer: a case report”. Cancer Res. Treat., 2010, 42, 48.

[6] Elalamy I., Canon J.L., Bols A., Lybaert W., Duck L., Jochmans K., et al.: “Thrombo-embolic events in cancer patients with impaired renal function”. J. Blood Disord. Transfus., 2014, 5, 202.

[7] Sud R., Khorana A.A.: “Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model”. Thromb. Res., 2009, 123, S18.

[8] Von Tempelhoff G.F., Heilmann L., Hommel G., Pollow K.: “Impact of rheological variables in cancer”. Semin. Thromb. Hemost., 2003, 29, 499.

[9] Von Tempelhoff G.F., Nieman F., Heilmann L., Hommel G.: “Association between blood rheology, thrombosis and cancer survival in patients with gynecologic malignancy”. Clin. Hemorheol. Microcirc., 2000, 22, 107.

[10] Von Tempelhoff G.F., Pollow K., Schneider D., Heilmann L.: “Chemotherapy and thrombosis in gynecologic malignancy”. Clin. Appl. Thromb. Hemost., 1999, 5, 92.

[11] Martino M.A., Williamson E., Rajaram L., Lancaster J.M., Hoffman M.S., Maxwell G.L., Clarke-Pearson D.L.: “Defining practice patterns in gynecologic oncology to prevent pulmonary embolism and deep venous thrombosis”. Gynecol. Oncol., 2007, 106, 439.

[12] Bouchard-Fortier G., Geerts W.H., Covens A., Vicus D., Kupets R., Gien L.T.: “Is venous thromboprophylaxis necessary in patients undergoing minimally invasive surgery for a gynecologic malignancy?” Gynecol. Oncol., 2014, 134, 228.

[13] Maxwell G.L., Myers E.R., Clarke-Pearson D.L.: “Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery”. Obstet. Gynecol., 2000, 95, 206.

[14] Khorana A.A., Connolly G.C.: “Assessing risk of venous thromboembolism in the patient with cancer”. J. Clin. Oncol., 2009, 27, 4839.

[15] Bakhru A.: “Effect of ovarian tumor characteristics on venous thromboembolic risk”. J Gynecol Oncol., 2013, 24, 52.

[16] Cairns R.A., Hill R.P.: “Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma”. Cancer Res., 2004, 64, 2054.

[17] Oranratanaphan S., Termrungruanglert W., Khemapech N.: “Incidence and clinical characteristic of venous thromboembolism in gynecologic oncology patients attending King Chulalongkorn Memorial Hospital over a 10 year period”. Asian Pac. J. Cancer Prev., 2015, 16, 6705.

[18] Caroline Edijana Omoti, Evarista Osime: “Haemorheological changes in cancer patients on chemotherapy”. Pak. J. Med. Sci., 2007, 23, 313.

[19] Lee A.Y., Peterson E.A.: “Treatment of cancer-associated thrombosis”. Blood, 2013, 122, 2310.

[20] Chew H.K., Wun T., Harvey D., Zhou H., White R.H.: “Incidence of venous thromboembolism and its effect on survival among patients with common cancers”. Arch. Intern. Med., 2006, 166, 458.

[21] Streiff M.B.: “Association between cancer types, cancer treatments, and venous thromboembolism in medical oncology patients”. Clin. Adv. Hematol. Oncol., 2013, 11, 349.

[22] Hwang S.G., Kim K.M., Cheong J.H., Kim H.I., An J.Y., Hyung W.J., Noh S.H.: “Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer”. Eur. J. Surg. Oncol., 2012, 38, 562.

[23] Yu M., Liu L., Zhang B.L., Chen Q., Ma X.L., Wu Y.K., et al.: “Pretreatment thrombocytosis as a prognostic factor in women with gynecologic malignancies: a meta-analysis”. Asian Pac. J. Cancer Prev., 2012, 13, 6077

[24] Yuan L., Liu X.: “Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism”. Mol. Med. Rep., 2015, 11, 2449.

[25] Satoh T., Matsumoto K., Uno K., Sakurai M., Okada S., Onuki M., et al.: “Silent venous thromboembolism before treatment in endometrial cancer and the risk factors”. Br. J. Cancer, 2008, 99, 1034.

[26] Noda K., Wada H., Yamada N., Noda N., Gabazza E.C., Kumeda K., et al.: “Changes of hemostatic molecular markers after gynecological surgery”. Clin. Appl. Thromb. Hemost., 2000, 6, 197.

[27] Carrier M., Lee A.Y., Bates S.M., Anderson D.R., Wells P.S.: “Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients”. Thromb. Res., 2008, 123, 177.

[28] Miller B., Heilmann L.: “Hemorheological parameters in patients with gynecologic malignancies”. Gynecol. Oncol., 33, 177.

[29] Von Tempelhoff G.F., Niemann F., Schneider D.M., Kirkpatrick C.J., Hommel G., Heilmann L.: “Blood rheology during chemotherapy in patients with ovarian cancer”. Thromb. Res., 1998, 90, 73.

[30] Tuktamyshov R., Zhdanov R.: “The method of in vivo evaluation of hemostasis: spatial thrombodynamics”. Hematology, 2015, 20, 584.